Rankings
▼
Calendar
APLS (Apellis Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena
APLS
Apellis Pharmaceuticals, Inc.
Mkt Cap
$3B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$1.0B
Net Income (TTM)
$22M
EPS (TTM)
$0.17
Free Cash Flow (TTM)
$45M
Gross Margin
89.8%
Op. Margin
5.5%
Net Margin
2.2%
FCF Margin
4.5%
P/S Ratio (TTM)
2.5x
P/E Ratio (TTM)
112.7x
YoY Rev Growth
+28.5%
Employees
—
Earnings Reports
▶
Q4 2025
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$45M
$37M
-$175M
Q2 23
$95M
$87M
-$120M
Q3 23
$110M
$88M
-$137M
Q4 23
$146M
$126M
-$85M
Q1 24
$172M
$152M
-$62M
Q2 24
$200M
$176M
-$29M
Q3 24
$197M
$163M
-$47M
Q4 24
$213M
$172M
-$26M
Q1 25
$167M
$132M
-$83M
Q2 25
$178M
$164M
-$33M
Q3 25
$459M
$434M
$223M
Q4 25
$200M
$170M
-$51M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
23.8x
—
Q2 23
13.7x
—
Q3 23
9.2x
—
Q4 23
6.4x
—
Q1 24
4.8x
—
Q2 24
4.0x
—
Q3 24
3.5x
—
Q4 24
3.2x
—
Q1 25
3.3x
—
Q2 25
3.3x
—
Q3 25
2.5x
56.1x
Q4 25
2.5x
112.7x
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$178M
-$178M
Q2 23
-$150M
-$151M
Q3 23
-$169M
-$169M
Q4 23
-$98M
-$98M
Q1 24
-$133M
-$133M
Q2 24
-$8M
-$8M
Q3 24
$34M
$34M
Q4 24
$19M
$19M
Q1 25
-$53M
-$53M
Q2 25
$4M
$4M
Q3 25
$108M
$108M
Q4 25
-$14M
-$14M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$259K
Q2 23
$372K
Q3 23
$47K
Q4 23
$95K
Q1 24
$293K
Q2 24
$90K
Q3 24
$0
Q4 24
$20K
Q1 25
$8K
Q2 25
$49K
Q3 25
$148K
Q4 25
$205K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
+211.8%
+53.4%
Q2 23
+481.8%
+30.6%
Q3 23
+400.5%
+41.4%
Q4 23
+545.9%
+23.7%
Q1 24
+284.3%
+6.6%
Q2 24
+110.3%
+6.4%
Q3 24
+78.3%
-1.4%
Q4 24
+45.2%
+3.4%
Q1 25
-3.2%
+6.7%
Q2 25
-10.6%
-7.6%
Q3 25
+133.0%
-3.6%
Q4 25
-5.9%
+5.2%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$29M
64.3%
Q2 23
$29M
30.8%
Q3 23
$22M
19.6%
Q4 23
$26M
17.9%
Q1 24
$30M
17.6%
Q2 24
$30M
15.0%
Q3 24
$27M
14.0%
Q4 24
$26M
12.4%
Q1 25
$27M
16.4%
Q2 25
$27M
15.2%
Q3 25
$28M
6.1%
Q4 25
-$83M
-41.4%
marketcaparena.com
OpEx Breakdown
R&D
G&A
S&M
SG&A
Quarter
R&D
G&A
S&M
SG&A
Q1 23
$110M
$102M
—
—
Q2 23
$96M
$111M
—
—
Q3 23
$79M
$146M
—
—
Q4 23
$69M
$142M
—
—
Q1 24
$85M
—
—
$129M
Q2 24
$78M
—
—
$128M
Q3 24
$89M
—
—
$122M
Q4 24
$76M
$38M
$83M
—
Q1 25
$86M
—
—
$129M
Q2 25
$67M
—
—
$131M
Q3 25
$68M
—
—
$143M
Q4 25
$74M
—
—
$147M
marketcaparena.com
Revenue Segments
Licensing And Other Revenue
Product
Quarter
Licensing And Other Revenue
Product
Q1 23
$6M
$39M
Q2 23
$5M
$90M
Q3 23
$11M
$99M
Q4 23
$8M
$139M
Q1 24
$9M
$163M
Q2 24
$21M
$179M
Q3 24
$20M
$177M
Q4 24
$21M
$191M
Q1 25
$17M
$150M
Q2 25
$7M
$171M
Q3 25
$281M
$178M
Q4 25
$10M
$190M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$765M
$0
$765M
Q2 23
$616M
$9M
$626M
Q3 23
$452M
$13M
$466M
Q4 23
$351M
$1M
$352M
Q1 24
$327M
$0
$327M
Q2 24
$360M
$8M
$368M
Q3 24
$397M
$0
$397M
Q4 24
$411M
$5M
$416M
Q1 25
$358M
$0
$358M
Q2 25
$371M
$0
$371M
Q3 25
$479M
$0
$479M
Q4 25
$468M
$0
$468M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
114M
+2.9%
Q2 23
119M
+4.8%
Q3 23
120M
+0.8%
Q4 23
121M
+0.8%
Q1 24
123M
+1.4%
Q2 24
124M
+0.8%
Q3 24
124M
+0.0%
Q4 24
124M
+0.0%
Q1 25
125M
+1.3%
Q2 25
126M
+0.5%
Q3 25
126M
+0.0%
Q4 25
126M
+0.0%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
—
—
FY 15
—
—
FY 16
—
—
FY 17
$0
39
FY 18
$0
87
FY 19
$0
235
FY 20
$670K
374
FY 21
$140K
476
FY 22
$98K
767
FY 23
$565K
702
FY 24
$1M
705
FY 25
$1M
733
marketcaparena.com